The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
A multicenter double‐blind placebo‐controlled trial of pergolide as an adjunct to sinemet® in Parkinson's disease
Abstract
Three hundred and seventy‐six subjects with advanced Parkinson's disease participated in a prospective, double‐blind placebo‐controlled study of the dopamine agonist pergolide mesylate as an adjunct to Sinemet®. At 6 months, patients randomized to pergolide had a statistically singnificant improvement in total Parkinson's score, scores of activities of daily living, motor function, number of “off” hours, Hoehn and Yahr stage, and numerous parameters of parkinsonian function including bradykinesia, rigidity, gait, and dexterity. This benefit was obtained with the addition of a mean dose of 2.94 mg of pergolide, which permitted a 24.7% reduction in dose of levodopa. Adverse reactions were, for the most part, mild, reversible, and not of major clinical significance. No significant cardiac or electrocardiographic abnormalities were detected. This study demonstrates that pergolide mesylate, as an adjunct to levodopa, is an effective antiparkinsonian agent that provides clinical improvement while permitting a reduction in levodopa dose.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An introduction to the free radical hypothesis in Parkinson's disease
Olanow, C. W. (1992) · Annals of Neurology · doi:10.1002/ana.410320703 · Cited by 382
Self-citation
Cited by
Pahwa, R., Factor, S. A., Lyons, K. E., Ondo, W. G., Gronseth, G., Bronte-Stewart, H., Hallett, M., Miyasaki, J., Stevens, J., & Weiner, W. J. (2006) · Neurology · doi:10.1212/01.wnl.0000215250.82576.87 · Cited by 499
Sleepiness in Parkinson's disease: A controlled study
Brodsky, M. A., Godbold, J., Roth, T., & Olanow, C. W. (2003) · Movement Disorders · doi:10.1002/mds.10429 · Cited by 169
Self-citationvan Laar, T. (2003) · CNS Drugs · doi:10.2165/00023210-200317070-00002 · Cited by 43
Metadata
- Authors
- Olanow, C. W., Fahn, S., Muenter, M., Klawans, H., Hurtig, H., Stern, M., Shoulson, I., Kurlan, R., Grimes, J. D., Jankovic, J., Hoehn, M., Markham, C. H., Duvisin, R., Reinmuth, O., Leonard, H. A., Ahlskog, E., Feldman, R., Hershey, L., & Yahr, M. D.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 1994-01
- Volume
- 9
- Issue
- 1
- Pages
- 40-47
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W2078512647
- Cited by
- 204
- References
- 1
- FWCI
- 7.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A multicenter double‐blind placebo‐controlled trial of pergolide as an adjunct to sinemet® in Parkinson's disease. https://app.cochat.ai/papers/10.1002/mds.870090107
- The paper
- Olanow, C. W., Fahn, S., Muenter, M., Klawans, H., Hurtig, H., Stern, M., Shoulson, I., Kurlan, R., Grimes, J. D., Jankovic, J., Hoehn, M., Markham, C. H., Duvisin, R., Reinmuth, O., Leonard, H. A., Ahlskog, E., Feldman, R., Hershey, L., & Yahr, M. D. (1994). A multicenter double‐blind placebo‐controlled trial of pergolide as an adjunct to sinemet® in Parkinson's disease. Movement Disorders. https://doi.org/10.1002/mds.870090107
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
